Composition comprising arabinogalactan and polyphenols from larch trees
The present invention includes a composition and method of treatment having arabinogalactan and polyphenols from larch trees for the use in prophylactic treatment of upper respiratory tract infections. The invention also includes treatment using such composition.
1. A method for reducing the number of upper respiratory tract infections in a subject having an increased susceptibility for an upper respiratory tract infection, the method comprising administering to the subject a composition comprising arabinogalactan and polyphenols from larch trees, wherein the composition comprises from about 1% (w/w) to about 4% (w/w) of polyphenols relative to a total amount of arabinogalactan and polyphenols in the composition, wherein the subject having an increased susceptibility for an upper respiratory tract infection develops at least three (3) episodes of an upper respiratory tract infection within six (6) months in untreated status.
2. The method of claim 1 , wherein the subject is a human subject.
3. The method of claim 1 , wherein the composition is administered to the subject on a daily basis.
4. The method of claim 3 , wherein the composition is administered to the subject for at least 30 days.
5. The method of claim 1 , wherein the composition is administered to the subject in a daily amount equivalent to about 0.5 g to about 15 g of the arabinogalactan and polyphenols.
6. The method of claim 1 , wherein the composition is administered to the subject in an amount of at least about 1.5 g per day.
7. The method of claim 1 , wherein the composition is administered to the subject with a food or a beverage.
8. The method of claim 1 , wherein the subject has a weakened immune system.
9. The method of claim 1 , wherein the subject has a medical condition selected from lung disease, a heart condition, a metabolic disease, a kidney problem, a blood disorder, morbid obesity, cancer, or HIV; or wherein the subject is taking a steroid medication.
10. The method of claim 2 , wherein the subject is selected from a subject being 65 years or older, and a subject aged six months to 4 years.
11. The method of claim 1 , wherein the upper respiratory tract infection is caused by a rhinovirus.
12. The method of claim 1 , wherein the upper respiratory tract infection is a common cold.
13. The method of claim 1 , wherein said administering reduces the number of common cold episodes in the subject when compared to subjects not being administered the composition.